查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976602

性行為感染感染檢測市場：依檢測類型、產品類型、技術、疾病類型、檢體類型、最終用戶和通路分類－2026-2032年全球預測

STD Testing Market by Test Type, Product, Technology, Disease Type, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，性行為感染感染檢測市場價值將達到 105.8 億美元，到 2026 年將成長至 112.2 億美元，到 2032 年將達到 160.3 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 105.8億美元
預計年份：2026年 112.2億美元
預測年份 2032 160.3億美元
複合年成長率 (%) 6.12%

對當前性行為感染檢測現狀的權威觀點，這種現狀受到創新、獲取壓力和不斷發展的醫療保健服務模式的影響。

由於技術進步、政策重點轉變和醫療服務模式演變等因素的共同作用，性行為感染（STI）檢測領域正經歷著快速且持續的變革。公共衛生計畫、臨床檢查室和照護現場機構都在積極回應日益成長的對更快、更準確、更便捷診斷的需求，同時還要應對諸如社會污名、報銷不均和法規環境波動等持續存在的障礙。這些矛盾正在改變從集中式參考檢查室到分散式照護現場機構等各種場所的檢測方法的開發、檢驗和實施方式。

分子診斷、非侵入性採樣、數位整合以及經銷模式的創新如何改變性行為感染感染檢測和臨床決策的提供方式？

該領域正經歷多重轉折點，這些轉折點正在改變臨床路徑、供應鏈和患者體驗。首先，分子診斷已從專業檢查室轉移到更貼近患者的場所，這得益於簡化的工作流程和強大的檢體到結果平台。這使得核酸擴增技術能夠提供更早、更可靠的檢測。同時，等溫擴增技術的進步和橫向流動化驗化學的改進縮小了快速檢測和檢查室檢測之間的性能差距，從而為臨床環境中的即時決策提供了更多選擇。

評估 2025 年關稅變化對整個診斷設備、試劑盒和檢測生態系統中最終用戶韌性的累積供應鏈和採購影響。

2025年推出的最新貿易政策變化對支撐性行為感染感染診斷生態系統的整個採購、製造和分銷管道產生了累積影響。影響進口設備、試劑盒和組件的關稅調整給供應鏈帶來了壓力，促使製造商和經銷商重新評估籌資策略和庫存管理實踐。因此，診斷檢查室、醫院和參考檢測中心的採購團隊不得不權衡確保持續獲得​​檢測服務的需求與營運現實（例如前置作業時間波動和與供應商的談判）之間的關係。

綜合細分分析揭示了測試類型、最終用戶需求、產品形式、技術選擇、通路、目標疾病和檢體類型如何決定策略重點。

詳細的細分分析揭示了性行為感染感染檢測領域中產品開發、分銷和臨床應用在多個維度上的差異。就檢測類型而言，培養檢測在抗菌藥物敏感性試驗和確診流程中仍然至關重要，而瓊脂培養和細胞培養則繼續支持一些專門的檢查室功能。核酸增幅檢查涵蓋了基於PCR的平台和等溫擴增方法。 PCR在靈敏度高的檢測中仍然發揮核心作用，而等溫擴增方法則提供了一種更簡單快捷的方式，適用於分散式環境。快速檢測包括橫向流動化驗和照護現場平台，這些平台優先考慮速度和易用性，而酵素免疫分析法和側向層析免疫檢測支持篩檢和流行病學監測。

區域流行病學、法規環境、生產能力和分銷策略如何影響世界各地檢測的部署狀況和獲取途徑的差異？

區域趨勢導致流行病學、法規結構、生產能力和醫療服務模式等方面有顯著差異，進而影響檢測計畫的實施。在美洲，積極的私部門參與和完善的檢測網路與公共衛生篩檢計畫並存。在數位化結果交付和廣泛分發管道的支持下，就地檢驗和居家篩檢在該地區日益普及。這些趨勢有利於那些將強大的檢測能力與以用戶為中心的設計以及與電子健康記錄和病例報告系統深度整合相結合的解決方案。

競爭格局洞察突顯了技術差異化、夥伴關係、監管策略和服務導向模式如何影響市場定位和滲透率。

性行為感染感染診斷領域的競爭趨勢是由技術差異化、策略夥伴關係以及超越核心檢測能力的基於服務的交付模式共同塑造的。主要企業正投資於提升分析靈敏度和特異性的能力，同時透過簡化工作流程和整合數位化報告來最佳化使用者體驗。這種組合為那些能夠支援在中心實驗室和以患者為中心的環境中部署、展現實際效用和完善品質系統的企業提供了機會。

經營團隊可採取的策略重點，以加強供應韌性、加速照護現場部署、整合數位化工作流程，並與監管機構和公共衛生合作夥伴合作。

產業領導者應採取能夠增強韌性、加速產品普及並最大限度地提升不同醫療環境下臨床應用效果的策略。優先考慮供應鏈多元化並確保關鍵零件的多個來源，可降低貿易中斷和關稅風險。投資本地生產和區域組裝將縮短前置作業時間並有助於符合監管要求。同時，加速利用等溫擴增和改進的側向流動化學技術開發就地檢驗和快速檢測方法，將使即時檢測結果能夠惠及當地社區和分散式醫療機構，從而實現及時治療和通知合作夥伴。

本研究結果的得出方法透明性（有關主要訪談、次要證據整合、細分分析和品質保證通訊協定的詳細資訊）。

本報告的研究採用了綜合性的混合方法，以確保分析的嚴謹性、情境有效性和可重複性。主要研究包括對臨床實驗室經理、照護現場專案管理人員、採購負責人和監管專家進行結構化訪談，以了解營運限制、推廣應用促進因素和採購考量。除訪談外，與診斷研發公司和分銷合作夥伴的討論也為了解產品開發藍圖和分銷策略提供了重要資訊。

一份簡潔、全面的分析報告，重點闡述了創新、營運韌性和跨部門合作如何塑造性行為感染檢測實施和普及之路。

總而言之，目前性行為感染感染檢測的現狀反映了技術進步與實施複雜性之間的平衡。儘管核酸擴增技術、照護現場平台和非侵入性採樣技術的進步正在擴展診斷能力，但供應鏈韌性、監管差異和分銷物流等實際操作因素仍然限制實施路徑。相關人員，將更有能力將創新轉化為更佳的臨床療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：性行為感染感染檢測市場

  • 培養試驗
    • 瓊脂培養法
    • 細胞培養
  • 核酸增幅檢查
    • 等溫擴增法
    • 基於PCR的
  • 快速檢測
    • 橫向流動化驗
    • 照護現場平台
  • 血清學檢測
    • 酵素免疫分析法
    • 橫向流動化驗

第9章：性行為感染感染檢測市場：依產品分類

  • 裝置
  • 成套工具
  • 軟體和服務

第10章：性行為感染感染檢測市場：依技術分類

  • 酵素免疫分析法
  • 等溫擴增
  • 橫向流動化驗
  • 基於PCR的

第11章：性行為感染感染檢測市場：依疾病類型分類

  • 披衣菌感染
  • 淋病
  • 皰疹
  • HIV
  • 梅毒

第12章 依檢體類型分類的性行為感染感染檢測市場

  • 血
  • 唾液
  • 棉花棒
  • 尿

第13章：性行為感染感染偵測市場：依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 就地檢驗設施
  • 參考測試機構

第14章：性行為感染傳染感染檢測市場：依通路分類

  • 離線
  • 線上

第15章：性行為感染感染檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：性行為感染感染檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章性行為感染感染檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國性行為感染感染檢測市場

第19章：中國性行為感染感染檢測市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Access Medical Laboratories Inc.
  • ARCpoint Labs
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • OraSure Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
Product Code: MRR-69324464D0F2

The STD Testing Market was valued at USD 10.58 billion in 2025 and is projected to grow to USD 11.22 billion in 2026, with a CAGR of 6.12%, reaching USD 16.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.58 billion
Estimated Year [2026] USD 11.22 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 6.12%

An authoritative orientation to the current sexually transmitted disease testing environment shaped by innovation, access pressures, and evolving care delivery models

The landscape of sexually transmitted disease testing is undergoing rapid and sustained transformation as technological advances converge with shifting policy priorities and evolving patterns of care delivery. Public health programs, clinical laboratories, and point-of-care providers are responding to rising demand for faster, more accurate, and accessible diagnostics while confronting persistent barriers such as stigma, inconsistent reimbursement, and variable regulatory environments. These tensions are reshaping how tests are developed, validated, and delivered across multiple settings, from centralized reference laboratories to decentralized point-of-care locations.

Diagnostics developers and health systems are prioritizing innovations that reduce time to result, expand non-invasive sampling, and enable multiplexed detection of pathogens to streamline clinical decision-making. At the same time, digital health integration and software-enabled workflows are improving data capture, reporting, and patient linkage to care. As a result, stakeholders across the value chain are increasingly focused on interoperability, quality assurance, and the practicalities of scaling novel testing modalities in diverse clinical and community contexts.

To navigate this environment, leaders must interpret technical advances in the context of operational realities and regulatory constraints while preserving equitable access. The following sections unpack the transformative shifts, tariff-related impacts, segmentation insights, and region-specific considerations that collectively define the current moment for STD testing.

How innovations in molecular methods, non-invasive sampling, digital integration, and distribution models are reshaping STD testing delivery and clinical decision-making

The field has experienced several transformative shifts that are altering clinical pathways, supply chains, and patient experiences. First, molecular diagnostics have migrated from specialized laboratories to near-patient settings through simplified workflows and robust sample-to-answer platforms, enabling nucleic acid amplification technologies to drive earlier and more reliable detection. Concurrently, advances in isothermal amplification techniques and improvements in lateral flow assay chemistry have narrowed performance gaps between rapid tests and laboratory-based assays, expanding options for immediate decision-making at the point of care.

Second, the expansion of non-invasive sample types such as saliva and self-collected swabs is lowering barriers to testing and enabling broader screening initiatives outside traditional clinical settings. This shift is complemented by software and services that support remote result delivery, patient follow-up, and electronic case reporting, creating more integrated care pathways. Third, distribution and procurement channels have diversified as manufacturers and distributors adopt omnichannel strategies, including direct sales, distributor networks, and online platforms that reach community-based organizations and home-testing consumers.

Finally, regulatory modernization and public health priorities have encouraged adaptive study designs and accelerated pathways for clinically-validated assays, while emerging attention to antimicrobial resistance underscores the need for diagnostics that inform treatment selection. Together, these shifts demand coordinated responses from developers, laboratories, and health authorities to ensure diagnostic performance, equitable access, and sustainability of testing programs.

Evaluating the cumulative supply chain and procurement consequences of 2025 tariff shifts on diagnostics instruments, kits, and end-user resilience across the testing ecosystem

Recent trade policy changes introduced in 2025 have produced cumulative effects across procurement, manufacturing, and distribution channels that serve the sexually transmitted disease diagnostics ecosystem. Tariff adjustments impacting imported instruments, kits, and component parts have pressured supply chains, prompting manufacturers and distributors to reassess sourcing strategies and inventory management practices. As a consequence, procurement teams in diagnostic laboratories, hospitals, and reference centers have had to balance the imperative for uninterrupted testing access with the operational realities of lead-time variability and supplier negotiation.

In response, some stakeholders have accelerated localization efforts for critical components and explored alternative suppliers across regions to reduce exposure to trade-related volatility. These adjustments have implications for product portfolios, as developers consider how instrument designs and consumable formats influence cross-border logistics and regulatory compliance. For point-of-care testing sites and online channels that rely on rapid replenishment, the tariff-driven dynamics have highlighted the importance of resilient distribution agreements and transparent pricing arrangements with manufacturers and distributors.

Moreover, tariffs have catalyzed renewed emphasis on software and services as value differentiators, with diagnostics providers investing in service packages that mitigate supply disruptions for end users. Regulatory pathways and reimbursement conversations must adapt alongside procurement strategies to preserve patient access to timely testing, and stakeholders are increasingly collaborating on contractual safeguards and contingency plans that protect routine screening and outbreak response capabilities.

Integrated segmentation analysis explains how test type, end-user needs, product form factors, technology selection, distribution channels, disease targets, and sample types drive strategic priorities

A granular view of segmentation reveals how product development, distribution, and clinical adoption vary across multiple dimensions of the STD testing landscape. When considering test type, culture tests remain relevant for antimicrobial susceptibility and confirmatory workflows, with agar-based culture and cell culture continuing to support specialized laboratory functions. Nucleic acid amplification tests encompass both PCR-based platforms and isothermal amplification methods; PCR maintains a central role for high-sensitivity detection while isothermal approaches enable simplified, rapid formats suited to decentralized settings. Rapid tests include lateral flow assays and point-of-care platforms that prioritize speed and ease of use, whereas serology testing through enzyme immunoassays and lateral flow immunoassays supports screening and epidemiological surveillance.

End users exhibit distinct operational requirements: diagnostic laboratories and reference laboratories prioritize throughput, quality control, and integration into laboratory information systems, hospitals and clinics focus on workflow efficiency and clinician-facing interpretability, and point-of-care testing sites emphasize ease of use, rapid turnaround, and linkage to care. Product types span instruments, where durability and compatibility with diverse consumables matter, kits that demand consistent supply chain assurance and shelf stability, and software and services that enhance data management, result reporting, and remote patient engagement. Technologies such as enzyme immunoassay, isothermal amplification, lateral flow assay, and PCR each present trade-offs between sensitivity, specificity, cost, and operational complexity.

Distribution channels-direct sales, distributors, and online channels-shape market reach and user support models, influencing how quickly new assays penetrate clinical practice. Disease-specific dynamics vary by pathogen: chlamydia and gonorrhea testing protocols often emphasize nucleic acid amplification for high diagnostic accuracy, herpes relies on a combination of direct detection and serology depending on clinical context, HIV testing integrates both rapid screening and confirmatory molecular assays, and syphilis diagnostics require sensitive serology with reflex testing strategies. Sample types influence user experience and adoption, with blood and serum samples remaining standard for serology, urine and swab specimens favored for many nucleic acid assays, and saliva increasingly used for user-friendly screening initiatives. Collectively, these segmentation layers inform product design, regulatory strategy, and commercialization pathways for developers and service providers.

How regional epidemiology, regulatory ecosystems, manufacturing capability, and distribution strategies shape differential adoption and access across global regions

Regional dynamics introduce critical contextual differences in epidemiology, regulatory frameworks, manufacturing capacity, and care delivery models that shape testing program implementation. In the Americas, substantial private sector participation and established laboratory networks coexist with active public health screening programs; the region shows strong uptake of point-of-care testing and home-based screening, supported by digital result delivery and broad distribution channels. These dynamics favor solutions that combine robust laboratory performance with user-focused design and strong connectivity to electronic health records and case reporting systems.

Europe, Middle East & Africa presents a heterogenous landscape characterized by stringent regulatory pathways in some markets, resource constraints in others, and variable disease prevalence across countries. Here, diagnostics developers must balance cost-effectiveness with rigorous validation and support capacity building for laboratory infrastructure. Partnerships with regional distributors and public health agencies are pivotal to expanding access and ensuring quality assurance, particularly for reference laboratories and programs focused on surveillance and outbreak response.

Asia-Pacific encompasses major manufacturing hubs and rapidly expanding diagnostic adoption, with a strong emphasis on scalable production, mobile health integration, and online distribution models. High-volume manufacturing capacity supports cost-competitive kit production, while rising investments in point-of-care platforms and telehealth services drive demand for non-invasive sampling and rapid result delivery. Across all regions, harmonizing regulatory submissions, strengthening local validation studies, and tailoring distribution strategies are essential to align product deployment with public health goals and clinical workflows.

Competitive landscape insights highlighting how technological differentiation, partnerships, regulatory strategy, and service-oriented models influence market positioning and adoption

Competitive dynamics in the STD diagnostics space are shaped by a mix of technological differentiation, strategic partnerships, and service-based offerings that extend beyond core assay performance. Leading developers are investing in features that improve analytical sensitivity and specificity while optimizing user experience through simplified workflows and integrated digital reporting. This combination supports adoption in both centralized laboratories and near-patient environments, creating opportunities for companies that can demonstrate real-world utility and robust quality systems.

Strategic alliances between instrument manufacturers, kit suppliers, and distribution partners are increasingly common as companies seek to accelerate market access and reduce time-to-adoption in clinical settings. Additionally, firms that pair diagnostics with software and services-such as connectivity solutions, training, and after-sales support-gain competitive advantage by addressing implementation barriers faced by hospitals, clinics, and point-of-care providers. Intellectual property around novel amplification chemistries and multiplexing approaches remains a differentiator, as does the ability to secure regulatory clearances across multiple jurisdictions.

Market actors are also exploring differentiated commercial models, including subscription-based access to instruments and consumables, bundled service agreements that include quality control and training, and targeted programs for public health customers that emphasize affordability and scale. These approaches reflect a broader pivot toward solutions that integrate product performance with practical deployment support to drive sustainable uptake.

Actionable strategic priorities for executives to strengthen supply resilience, accelerate point-of-care uptake, integrate digital workflows, and collaborate with regulators and public health partners

Industry leaders should pursue strategies that enhance resilience, accelerate access, and maximize clinical impact across diverse care settings. Prioritizing supply chain diversification and dual-source procurement for critical components will reduce exposure to trade disruptions and tariffs while investments in localized manufacturing or regional assembly can shorten lead times and support regulatory alignment. Concurrently, accelerating development of point-of-care and rapid testing modalities that leverage isothermal amplification and improved lateral flow chemistries will expand reach into community and decentralized settings where immediate results facilitate timely treatment and partner notification.

Leaders should also strengthen digital integration by embedding connectivity, automated reporting, and decision-support capabilities into test platforms and service offerings. This integration improves surveillance, simplifies case management, and enhances the value proposition for hospitals and public health partners. Commercially, adopting omnichannel distribution strategies-combining direct sales for large institutional customers, distributor relationships for regional penetration, and online channels for broader consumer access-will optimize market reach and responsiveness.

Finally, organizations should engage proactively with regulators and public health stakeholders to streamline validation pathways, participate in collaborative studies that demonstrate clinical utility across diverse populations, and design pricing and access programs that reduce barriers for high-need communities. By coupling technological innovation with pragmatic deployment strategies and stakeholder engagement, firms can drive sustainable improvements in testing coverage and clinical outcomes.

Methodological transparency detailing primary interviews, secondary evidence synthesis, segmentation analysis, and quality assurance protocols used to derive research findings

The research underpinning this report employed a comprehensive mixed-methods approach designed to ensure analytical rigor, contextual relevance, and reproducibility. Primary research included structured interviews with clinical laboratory directors, point-of-care program managers, procurement officers, and regulatory specialists to capture operational constraints, adoption drivers, and procurement considerations. These interviews were supplemented by consultations with diagnostic developers and distribution partners to understand product development roadmaps and channel strategies.

Secondary research encompassed systematic review of peer-reviewed literature, regulatory guidance documents, white papers, and publicly available technical specifications to validate performance characteristics and technology attributes. Data triangulation methods were applied to reconcile insights from primary interviews with documented evidence, ensuring consistency across qualitative and quantitative indicators. Segmentation analysis was performed across test type, end-user category, product typology, technology, distribution channel, disease target, and sample type to derive actionable insights for developers and purchasers.

Quality assurance protocols included cross-validation of interview findings, iterative review cycles with subject-matter experts, and transparent documentation of assumptions and limitations. Ethical standards for interview consent and data handling were observed throughout. While the methodology emphasizes current, evidence-based analysis, the report avoids speculative forecasting and instead focuses on empirical drivers and pragmatic implications for stakeholders.

A concise synthesis emphasizing how innovation, operational resilience, and cross-sector collaboration determine the trajectory of STD testing implementation and access

In synthesis, the current STD testing landscape reflects a balance between technological progress and implementation complexity. Advances in nucleic acid amplification, point-of-care platforms, and non-invasive sampling are expanding diagnostic capabilities, yet operational realities such as supply chain resilience, regulatory variability, and distribution logistics continue to temper adoption pathways. Stakeholders who align product design with end-user workflows, invest in digital connectivity, and proactively manage procurement risks will be better positioned to translate innovation into improved clinical outcomes.

Regional differences underscore the importance of tailored strategies, whether that means leveraging manufacturing strengths and online channels in Asia-Pacific, navigating regulatory and public health partnerships in Europe, Middle East & Africa, or integrating point-of-care and home-testing models across the Americas. Disease-specific needs and sample type considerations further refine deployment choices, informing where multiplex assays, serology platforms, or culture-based confirmation remain most appropriate. Ultimately, cross-sector collaboration among manufacturers, laboratories, clinicians, payers, and public health authorities is essential to scale testing programs that are both effective and equitable.

Moving forward, disciplined attention to quality, interoperability, and stakeholder engagement will determine which innovations achieve sustainable integration into clinical practice. By focusing on pragmatic implementation and resilient commercial strategies, the sector can expand access to high-quality testing and strengthen the continuum of care for individuals and communities affected by sexually transmitted infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. STD Testing Market, by Test Type

  • 8.1. Culture Tests
    • 8.1.1. Agar Based Culture
    • 8.1.2. Cell Culture
  • 8.2. Nucleic Acid Amplification Tests
    • 8.2.1. Isothermal Amplification
    • 8.2.2. PCR Based
  • 8.3. Rapid Tests
    • 8.3.1. Lateral Flow Assays
    • 8.3.2. Point Of Care Platforms
  • 8.4. Serology Tests
    • 8.4.1. Enzyme Immunoassay
    • 8.4.2. Lateral Flow Assays

9. STD Testing Market, by Product

  • 9.1. Instruments
  • 9.2. Kits
  • 9.3. Software And Services

10. STD Testing Market, by Technology

  • 10.1. Enzyme Immunoassay
  • 10.2. Isothermal Amplification
  • 10.3. Lateral Flow Assay
  • 10.4. PCR Based

11. STD Testing Market, by Disease Type

  • 11.1. Chlamydia
  • 11.2. Gonorrhea
  • 11.3. Herpes
  • 11.4. HIV
  • 11.5. Syphilis

12. STD Testing Market, by Sample Type

  • 12.1. Blood
  • 12.2. Saliva
  • 12.3. Swab
  • 12.4. Urine

13. STD Testing Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals And Clinics
  • 13.3. Point Of Care Testing Sites
  • 13.4. Reference Laboratories

14. STD Testing Market, by Distribution Channel

  • 14.1. Offline
  • 14.2. Online

15. STD Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. STD Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. STD Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States STD Testing Market

19. China STD Testing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Access Medical Laboratories Inc.
  • 20.7. ARCpoint Labs
  • 20.8. Becton Dickinson and Company
  • 20.9. Bio-Rad Laboratories, Inc.
  • 20.10. Danaher Corporation
  • 20.11. F. Hoffmann-La Roche AG
  • 20.12. Hologic, Inc.
  • 20.13. Laboratory Corporation of America Holdings
  • 20.14. OraSure Technologies, Inc.
  • 20.15. Quest Diagnostics Incorporated
  • 20.16. Quidel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STD TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STD TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. GCC STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. G7 STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. NATO STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. NATO STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. NATO STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)